SCC
TVGN icon

Spring Creek Capital’s Tevogen Bio Holdings TVGN Stock Holding History

Spring Creek Capital’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,000
Closed -$3M – 86
2022
Q1 		$3M Buy
+6,000
New +$2.98M 0.12% 174

Other funds holding TVGN

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return

Spring Creek Capital's TVGN Position: Q2 2022 in Review

Spring Creek Capital sold out of Tevogen Bio Holdings (TVGN) in Q2 2022, closing a stake of 6,000 shares — an estimated $3M sold.

Spring Creek Capital first reported a position in TVGN in Q1 2022 and held it in 1 quarter. The position peaked at $3M in Q1 2022. 67 funds tracked by Wall St. Rank hold TVGN as of Q2 2022.

  • Spring Creek Capital reported no remaining Tevogen Bio Holdings position as of Q2 2022 after selling out during the quarter.
  • Spring Creek Capital sold 6,000 Tevogen Bio Holdings shares in Q2 2022, an estimated $3M.
  • Spring Creek Capital first reported a position in Tevogen Bio Holdings in Q1 2022 and held it in 1 quarter.
  • Spring Creek Capital's Tevogen Bio Holdings position peaked at $3M in Q1 2022.
  • 67 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.